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Background
Recent advances in assay technology led to major
improvements in how HIV-1 neutralizing antibodies are
measured. A luciferase reporter gene assay performed in
TZM-bl (JC53bl-13) cells has been optimized, and many
performance parameters of this assay have been validated.
Because this assay has been adopted by multiple laborato-
ries world-wide, an external proficiency testing program
was developed to qualify laboratories to perform a Good
Clinical Laboratory Practice (GCLP) compliant neutraliz-
ing antibody assay for HIV/AIDS vaccine clinical trials.
Methods
The program was optimized by conducting three inde-
pendent rounds of testing, with an increased level of strin-
gency from the first to third round. Results from the
participating domestic and international laboratories
improved at each round as factors that contributed to
inter-assay variability were identified and minimized. Key
contributors to increased agreement were experience
among laboratories, standardization of reagents and
adherence to GCLP.
Results
Based on results from the three rounds of testing, stand-
ardized proficiency test kits were assembled at QBI, Inc.
Each kit consists of identical stocks of Env-pseudovirus
and five blinded serologic reagents. At the beginning of
the external proficiency program, five experienced refer-
ence laboratories will utilize the kits, in three repeats, to
derive gold standard reference values and acceptance
intervals for each antibody-isolate combination. The
acceptance interval is defined by a 90% prediction interval
with mean and variance estimated using logarithm trans-
formed ID50 values measured in the five reference labora-
tories.
Conclusion
A 2-fold systematic difference in ID50 values was set as the
acceptance criteria to qualify a lab such that results of two
vaccine trials, each with 30–50 volunteers, could be com-
pared, by qualified laboratories, with adequate statistical
power to detect moderate differences in the magnitude
and breadth of the neutralizing antibody response. This
program is jointly sponsored by the NIH and the Collab-
oration for AIDS Vaccine Discovery.
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